The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.

The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.

Pharma continues to be targeted by cyber criminals – the latest being India’s top-ranked company, Sun Pharma. Experts highlight some of the key vulnerabilities and why firms need to prioritize cyber resilience.

Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.

The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.